Skip to main content
. 2022 Jun 14;14(6):1265. doi: 10.3390/pharmaceutics14061265

Figure 1.

Figure 1

Schematic illustration of construction of SIM@HA-MSN for atherosclerosis management. (A) Scheme of fabrication process and administration route of SIM@HA-MSN. (B) Illustration of SIM@HA-MSN therapy which can potentially alleviate atherosclerosis through long circulating, enzyme-responsive drug release, macrophage targeting, and anti-inflammatory and anti-foaming effects. (Created by Biorender).